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Abstract
Plant molecular farming describes the production of recombinant proteins and other
secondary metabolites in plants. This technology depends on a genetic transformation
of plants that can be accomplished by the methods of stable gene transfer, such as
gene transfer to nuclei and chloroplasts, and unstable transfer methods like viral
vectors. An increasing quest for biomedicines has coincided with the high costs and
inefficient production systems (bacterial, microbial eukaryotes, mammalian cells,
insect cells, and transgenic animals). Therefore, transgenic plants as the bioreactors of
a new generation have been the subject of considerable attention with respect to their
advantages, such as the safety of recombinant proteins (antibodies, enzymes, vaccines,
growth factors, etc.), and their potential for the large-scale and low-cost production.
However, the application of transgenic plants can entail some worrying concerns,
namely the amplification and diffusion of transgene, accumulation of recombinant
protein toxicity in the environment, contamination of food chain, and costs of
subsequent processing. The given threats need to be the subject of further caution and
investigation to generate valuable products, such as enzymes, pharmaceutical
proteins, and biomedicines by the safest, cheapest, and most efficient methods.
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1. Introduction
Molecular farming is a biotechnological program that includes the genetic modification of
agricultural products to produce proteins and chemicals for commercial and pharmaceutical
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purposes. A vast majority of developing countries cannot afford the high costs of medical
treatments resulted from the existing methods. Hence, we need to produce not only the new
drugs but also the cheaper versions of the present samples in the market. Molecular farming
can offer efficient solutions for the current growing need for the biomedicines [1]. Plants
provide an inexpensive and simple system for the production of valuable recombinant proteins
on large scale, and compared to the other production systems, they have numerous advantages
in terms of economy, safety, and applicability. Though using transgenic plants has entailed
some sorts of limitations and concerns, the optimization has been operated for solving the
existing problems. Normally, the production of pharmaceutical proteins has been largely
concentrated by the technology of molecular farming in plants, also plants can be used for the
production of food supplements, biopolymers, industrial enzymes, and proteins in the
investigations (avidin, β-glucuronidase, etc.). Prior production systems, including bacteria,
microbial eukaryotes (yeasts, double-stranded fungi), animal cells, and transgenic animals, as
a result of their limitations, were replaced by transgenic plants. The primary recombinant
pharmaceutical proteins, extracted from the plants (hormones of human growth), and the first
recombinant antibodies were generated from transgenic plants, respectively, in 1986 and 1989
[2, 3]. In 1997, the first recombinant protein, avidin (egg protein) was produced in a transgenic
maize for industrial uses [4]. These applications proved that plants can be converted into
bioreactors to produce a wide range of recombinant proteins. Many years had already passed
when it was proved that plants were even able to produce several complexes of functional
mammal proteins with the pharmacological functions, such as human serum proteins, growth
regulators, antibodies, vaccines, hormones, cytokines, and enzymes [5]. An increasing request
for the biomedicines was aligned with the high costs and inefficiency of existing production
systems [6] including yeasts, bacteria, animal cells [7], and transgenic animals [8].
The aim of this study is to review the technologies of molecular farming, limitations and
advantages of plant systems, challenges, bio-security, public acceptance of molecular farming.
2. The strategies of plant transformation
Plant molecular farming depending on the production of transgenic plants has been operated
by two general methods as the following:
2.1. Stable or permanent expression systems
a. Stable nuclear transformation: Stable nuclear transformation refers to the integration of
genes or nominated foreign genes into the nuclear genome of plants, which results in the
change of genetic structures and consequent expression of transgenes after integration with
the host genomes. The largest amount of recombinant proteins has been produced by one of
the most common methods of stable nuclear transformation. A method exploited for aggre‐
gating proteins in dried beans of maize culminates in a long-term storage in the beans at the
room temperature without decomposition of proteins [9]. In addition, it has a considerable
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potential for producing crops like cereals that actually grow everywhere. However, a long
production cycle for some crops and their potential collisions with natural species or food
products have restricted the wide acceptance of this method [10].
b. Stable plastid transformation: Plastid transformation offers a remarkable solution in
comparison to that of nuclear transformation since it has numerous advantages including
preventing transgene escape through amphimixis (because plastids are inherited through the
maternal tissue in the majority of species.) and absence of chloroplasts in pollen and conse‐
quent improbability of their transfer, which reduces environmental concerns [11, 12]. The
transformed transgenic plants with homoplasmic chloroplasts (all chloroplasts carry trans‐
genes) were selected after several generations of plant regeneration from bombarded leaf
explants. Selection was conducted on a medium containing spectinomycin or combined with
streptomycin. The researchers [13, 14] have already extracted a human pharmaceutical protein,
more than 3% to 6%, from the total soluble proteins in the chloroplasts of tobacco. Recently,
Oey et al. [75] reported a very high level (70% of an entire soluble protein) for a protein
antibiotic with the chloroplast system, which, till today, has been the highest concentration of
recombinant proteins. Despite this, the great potential of plastid transformation has some
functional limitations. Although this technology has been developed in other species such as
tomatoes, lettuce, soy, and eggs [15, 16], in the current situation, chloroplast transformation
only in tobacco is practically possible, but unfortunately this plant is inedible and full of
poisonous alkaloids; in addition, long lasting storage in refrigerators will bring about changes
in protein stability [9].
c. Plant cell suspension culture: This method involves the removal of cell walls and gene
transfer to the obtained protoplasts and suspension culture. The purification system and its
downstream processing are cheaper and easier [17]. In addition, the use of suspension culture
can decrease heterogeneity in proteins and sugar (N-glycans) regarding the uniformity of the
type and size of cells [5]. Furthermore, as a fast system there is no need for the production of
transgenic plants; however, the cell lines can be produced after a few months [18, 19]. Some
samples of plant suspension cultures can be used for producing biomedicines, including
vaccines of Newcastle disease virus of chicks approved by the Center for Veterinary Biology
and recombinant human glucocerebrosidase for treating diabetes (www.protalix.com) [19].
Though this method is cheaper, safer, and easier in comparison to the other methods of genetic
manipulation, cell suspension has not yet been suggested as an optimal production choice of
production in plant systems. This is due to a belief that the ultimate products and their usability
are constrained by reducing the level of recombinant proteins during the stationary phase
because of the enhanced proteolytic activity [20].
2.2. Temporary or transient expression systems
A transient production may be the fastest system for plant molecular farming [21]. Nowadays,
these are the systems routinely applied for verifying expression constructs during a few weeks
for a significant amount of proteins [22]. The given systems include the following methods:
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a. Agrobacterium transformation method: Infiltration of recombinant agrobacterium
suspension into tobacco leaf tissue is achieved without stable gene transfer, which
facilitates the transfer of T-DNA to a very high percentage of cells, where the transgenes
are expressed at a high level without a stable transfer of genes. Presently, this method has
been very efficient for the production of clinical biomedicines with a fast expansion
[22-24].
b. Viral infection methods: The viral infection method depends on the capability of plant
viruses, such as tobacco mosaic virus and X potato virus, which functions as a vector to
convey foreign genes into plant genomes without fusing with the genome of that plant
[25].
c. Magnifection system: Expression systems based on viral vectors and agrobacterium
methods suffer from some constraints for the co-expression of two or more polypeptides
required for the production of hetero-oligomeric proteins [26]. Thus, a new transient
expression system known as MagnICON technology has been developed by Icon Genetics
Company. This method includes removing coat proteins (responsible for systemic
movement) of non-competitive virus stains and systemic delivery of the derived viral
vectors to all of the plants using agrobacterium as the medium of primary infection. This
method not only optimizes the infection but also significantly increases proliferation, and
finally results in the co-expression of several polypeptides and the rise of functional
protein production more than 100 times.
3. The advantages of utilizing transgenic plants as bioreactors
Comparison of different expression systems (see Table 1) reveals the advantages of plants in
comparison with other expression systems as follows:
• The healthiness of derived products (plants cannot be the host of human pathogens and
bacterial toxins).
• Capability of post-translational processing (respecting the features of eukaryotic cells).
• The possibility of using breeding methods and sexual crosses to obtain active recombinant
multi-chain proteins (therefore, there is the possibility of producing antibodies without
application of a double transformation).
• Reducing the costs of production (plants can produce biological materials by the use of
carbon dioxide, solar energy, and inorganic materials. Moreover, the scale of production
can be manipulated regarding scalability).
• Reducing the costs of storage and transportation of recombinant proteins (when they are
produced in dry textures like grains).
• Removing the purification step (when the plant tissues containing recombinant protein are
edible) [1].
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Characteristics Bacteria Mammalian cellculture Transgenic plants
Plant cell
culture
Production cost Average High Low Low
Post-translational modifications No Yes Yes Yes
Function High Average High High
Protein stability Yes Yes Yes in seeds Yes
Table 1. Comparison of Various Expression Systems for Producing Recombinant Proteins
4. The limitations and optimization of plant production systems
4.1. The problem of product shortage or the same recombinant proteins
4.1.1. 3.1.1. Optimization of expression of transcripts
To optimize the expression of  transcripts,  a  widely used strategy is  the use of  building
promoters,  such  as  cauliflower  mosaic  virus  35S  RNA  promoter  and  maize  1-ubiquitin
promoter,  respectively,  suitable  for  spilt-cotyledons  and  single-cotyledons  [27].  Tissue-
specific  and  organ-specific  promoters  are  used  for  stimulating  the  expression  of  trans‐
genes (antigen vaccine HBsAgM, single-chain variable fragment Maureen G4, and Human
interferon-α) in some tissues or organs, such as tubers, seeds, and fruits [28, 29]. The given
specific  expression  of  tissues  prevents  the  accumulation  of  recombinant  proteins  in
vegetative organs, which can have a negative impact on plant growth; for example, palatine
is a gland-specific promoter; i.e.,  the protein is expressed in the gland but not in leaves;
and also ubiquitin promoter is specified for the embryonic tissues of plants. Transcription
factors (e.g.,  AlcR) can act as the invigorator of promoters to increase the level of trans‐
gene expression [30].  The stability of  transcripts of  genes can be achieved by co-expres‐
sion of the specified gene and an RNA silencing inhibitor [31].
4.1.2. Optimization of translation
Expression constructs can be designed for guaranteeing the efficiency of translation and the
sustainability of transcripts. As an instance, the removal of 5' untranslated region and natural
´3 for foreign genes and introducing the leader sequence of tobacco mosaic virus RNA, RUB13
rice polyubiquitin gene, alfalfa mosaic virus, or tobacco viruses in the expressions, all,
individually, have shown a significant increase in the level of transgene expressions [32, 33].
In addition to the leader sequences, expression cassettes can be designed with the AU-rich
sequences in 3' untranslated regions, which may change or be removed as the editing sites for
ensuring the stability of transcript. It is also proved that every organism shows codon usage
deviations that may be the subject of importance for adapting the coding sequence of heter‐
ologous genes for the host gene to optimize the efficiency of translation. In this regard, the site
of initial translation from heterologous protein to pair with Kozak consensus sequence, with
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the application of GCTTCCTCC sequence, started after codon or ACC, or ACA had been
changed before that. It is better to unscientifically estimate codon changes rather than their
real amount considering the changes in the expression level of transgenes in similar systems
and the use of similar structures. To this end, an increase of codon combinations of (A/G)(a/c)
(a/g)AUG and (A/g)(u/C)(g/C)AUG for the optimal operation of translation was, respectively,
reported in Arabidopsis and rice. The given change in transgene expression could be due to
the position effect, number of transgene copies, or gene silencing.
Regarding the effect of position, expression cassettes can be designed to have nuclear matrix
attachment regions for ensuring the transgene insertion in proper sites for stimulating
transcription factors for promoters. Furthermore, the problem of position effect can be
prohibited by targeting the transgene to plastids. To optimize the production of single-
cotyledon transgene, the strategies that include the use of specific genetic elements containing
cAMP response elements for a simultaneous transfer with transgene in T-DNA are used. In
addition, one new technology, including the structure of an artificial autonomous mini-
chromosome, can genetically materialize excellent possibilities with several advantages,
namely genetic stability due to the absence of gene silencing and position effect.
4.1.3. Optimization of protein stability
To optimize the stability of recombinant proteins, known as the most important limiting factor
for the function of molecular farming [34], the targeting of proteins into certain intracellular
parts is demanded. The intracellular targeting not only increases protein stability but also
determines the processing type of dependent protein. This can be applied for the optimization
of isolation and procedures of purification by the fusion proteins and targets with high affinity
[27]. Targeting of proteins can be done by the following pathways and organelles,
• The intracellular parts, like protein storage vacuoles, have been discovered for the accumula‐
tion of recombinant proteins [30].
• Cathepsin D inhibitor can act as the agent of stability of protein structures to protect the
targeted recombinant proteins in the cytosol of plants [35]. Recombinant protein production
through this signal has been proved to be very effective and economical [36-38].
• To protect proteins from cytosolic degradation, these proteins can be targeted by fusion to
a C-terminal tail without a forced passing through the lumen of the endoplasmic reticulum
to the membrane surface [39]. To enhance the ease of purification, proteins can be fused to
oleosin proteins as oil bodies in order to target protein expression with the oil bodies of seeds.
• The proteins, like in glycosylation, that do not need post-translation modifications for their
activity, can be targeted to chloroplast since post-translation modifications are not conduct‐
ed in these organelles [40].
• Targeting for accumulation in endoplasmic reticulum is accomplished by two methods: one
is adding SEKDEL endoplasmic reticulum signals to the end of C-protein, and the other is
using fused N or C signals with y-zein. Endoplasmic reticulum is an oxidizing environment
with high amounts of chaperone proteins and low levels of proteases. This pathway is suitable
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for the proteins that need post-translational modifications (e.g., glycosylation) [76]. The
breakdown of proteins by proteases (proteolytic degradation) outside the cell is another
noticeable factor for investigating the plant-based production of biomedicines.
4.2. Challenge of glycosylation (protein quality)
Glycosylation refers to the covalent binding of sugars to proteins in order to increase close-
packing, biological activity, solubility, and biological functionality [5]. Glycosylation takes
place in plants in the secretory pathway of endoplasmic reticulum and golgi apparatus. The
glycosylation patterns of plants and animals differ in the composition of N-glycans; plants add
residues of α (1, 3) fucose and β-(1,2) xylose to N-glycans of their protein, but animals add
residues of (1 and 6) fucose, glucose, and sialic acid to N-glycans. These differences can be
problematic for humans when medical animal proteins extracted from plants are used (Krupp
et al., 2003); consequently, a correct human N-glycosylation demands a plant engineering. A
number of strategies for changing the pattern of N-glycosylation in plants have been elaborated
as following [71]:
• The use of purified enzymes of β-(1,4) galactosyltransferase and Sialyltransferase for making
glass transitions in the recombinant proteins derived from plants.
• Co-expression of β-(1,4) galactosyltransferase human enzyme with the target transgene in
transgenic plants.
• Prohibiting the activity of fucosyltransferase and xylyltransferase enzymes.
• Targeting pharmaceutical proteins to the endoplasmic reticulum in order to avoid the
addition of protective N-glycans.
4.3. Selecting appropriate host plants
Major economical factors in appointing an appropriate host include the total biomass yield,
storage characteristics, ease of transport, value of recombinant proteins, maintenance costs, its
availability for workers, required area, duration of production cycle, cost of subsequent
products, and edibility [27, 34]. In addition to the economical analysis, a sufficient host should
be appropriate in terms of transformation and regeneration [34, 72]. In addition to the high
potential of tobacco for transformation and regeneration, it has the majority of the aforemen‐
tioned economic benefits [27, 41, 42]. However, tobacco (except the cultivar 81 V9) [43] contains
high amounts of toxic combinations, nicotine and other alkaloids, that cannot be removed
during the purification process. In spite of this, alternative forage crops like alfalfa and lettuce
are being investigated and discovered as a suitable host for molecular farming [44]. However,
forage plants generally suffer from the problem of instability of expressed proteins, by which
drying and freezing of the leaves and immediate processing following the harvest have been
inevitable [27]. The seed-based expression of proteins is considered to be more ideal regarding
the fact that it neither affects the growth of plants nor needs the freezing of leaves or immediate
processing after harvest, and it allows the long-term storage of proteins at a limited tempera‐
ture without decreasing the level of activity [45, 46]. In this regard, grains, especially rice and
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corn, have been cited as the superior ones. Maize has abundant advantages, such as having
the highest rate of biomass yield among food crops and ease of transformation and production
increase [47]. The high amount of protein (20%-40%) in the grains of legumes with remarkable
levels of self-pollination in soy and peas is the main reason for transgenes of these plants for
protein accumulation [48-50].
5. Predicting the intracellular localization of the recombinant protein
The importance of intracellular localization of proteins is due to the functional consequences
of proteins. Therefore, the problem of intracellular localization of amino acid sequences has
been the subject of great attention in the community of bioinformatics. Thus, various methods,
like searching for targeted signals, have been presented with respect to a prediction that
various proteins are produced in different intercellular segments [51].
6. Proteins and biomedicines produced in plants
Plants are able to produce those bacterial and viral recombinant antigens that preserve the
capability of making the structures Type IV similar to those witnessed in mammalian systems,
and the post-translational modifications are operated to maintain the biological activity of
proteins. The most important issue is vaccine production in the edible tissues of transgenic
plants, which is a very safe and effective method in vaccination.
The biomedicines produced in plants are as follows:
• Antigens for the production of edible vaccines: Antigens, used for generating an immune
response resulting in immunity against diseases in human proteins, are expressed from
different pathogens in plants. Those vaccines derived from plants have been so far induced
immunity against rabies virus, hepatitis B, rotavirus, HIV, and other pathogens.
• Monoclonal antibodies: Widespread application of antibodies has lead to the study of new
methods in order to strengthen efficiency and reduce the cost of producing antibodies.
Among the studied methods, using transgenic plants as bioreactors are known as the most
efficient one. While designing therapeutic antibodies in the production of recombinant
expression systems, the apprehension of the functioning mechanisms of antibodies is
essential. Although the primary function of antibodies is actualized by binding to antigens,
it does not act as a protective performance. Some antibodies have a direct neutralizing
impact, for instance blocking the bacteria or the active sites of the pathogenic factors such
as enzymes. The antibodies produced in plants incorporate Immunoglobulin G (IgG) and
Immunoglobulin A (IgA), IgA and IgG shimmer molecules, IgG and IgA secreted molecules,
Single-Chain variable fragment, fragment antigen-binding, and second variable of heavy
and light chains [52-54].
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• Pharmaceutical proteins: Some samples of biomedicines recently expressed in plants
include erythropoietin, interferon, hirudin, aprotinin, Leu-enkephalin, somatotropin of
human growth hormone [55, 56].
• Non-pharmaceutical proteins derived from plants or industrial proteins belong mainly to
the enzymes that include avidin, trypsin, aprotinin, β-glucocerebrosidase, peroxidase and
cellulose, etc., listed by Basaran and Rodriguez-Cerezo [73] and now available in the market.
Molecular farming of destructive enzymes of the cell walls such as cellulose, hemicellulase,
xylanase, and particularly ligninase provide a great status for the biofuel industry respecting
cellulosic ethanol [57, 58].
7. Molecular farming and metabolic engineering, an opportunity for
producing plants with a high technology
Molecular farming and metabolic engineering make the production of new high-tech products
possible. There is a driving force backing molecular farming that makes its costs much less
than traditional farming. Chlamydomonas reinhardtii, as a unicellular alga, is one of the most
recent production projects examined by Franklin and Mayfield. C. Reinhardtii is the only plant
whose transformation was operated in its all segments containing DNA (nucleus, plastid, and
mitochondria). Unique features of the moss system bring about the possibility of removing
target genes and purification of the proteins secreted from the culture medium. The target gene
was omitted to get rid of the nuclear genes for glycosylation. The first step towards the long-
term goals of reengineering mechanism in modifications of plant proteins is setting a new
standard in all systems of plant expressions in order to humanize the biomedicines produced
in plants [59].
8. Purification and downstream processing of the recombinant proteins
Recovery usually includes the process and breakdown of plant tissues, protein extraction,
solid-liquid separation, and protein concentration while purification encompasses safety
protection, liquid-liquid extraction, membrane filtration, chromatography, etc. The processing
of leaves requires a particular attention; leaves should be processed immediately after the
harvest or frozen to prevent protein degradation by proteases, whereas seeds can be stored
for a long period of time due to the less probability of destruction of recombinant proteins
expressed in seeds. Using the secretory systems of cells can also be beneficial since disinte‐
grating plant cells throughout recovery is not required; thus, the release of phenolic com‐
pounds can be avoided while the recombinant proteins can be unstable in culture mediums.
Another way of facilitating the recovery of proteins is utilizing continuous labels. Protein labels
must be removed after purification so that the structure of purified protein can change into its
natural position. The technology of oleosin fusion, through which the gene sequence of
recombinant proteins is fused to the sequence of a special internal oil protein called oleosin in
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safflower and canola, is separated after the digestion of internal protease following protein
purification [1].
9. Costs of subsequent processing
The costs of subsequent processing of the recombinant proteins derived from plants have been
estimated about 80% of the total production costs [60, 61]. This is why so much attention has
been paid at sufficient strategies for reducing the costs to the least amount. The application of
watery textures like tomatoes as a production system has been expanded because of their
potential for reducing the costs via the ease of extracting from their textures in comparison
with those of dry tissues like grains [34, 62]. In addition, tomatoes are highly regarded as a
reputed host crop in terms of its bio-safety because these plants grow in greenhouses without
worrying about the preservation of transgenic plants.
Nowadays, oil bodies of oilseed agricultural products, like the seeds of safflower and mustard,
are being exploited by the application of oleosin fusion technology developed by SemBioSys
Genetics in order to facilitate the purification of recombinant proteins and reduction of
subsequent costs (http://www.sembiosys.com/). The strategies including targeting of recombi‐
nant proteins for the seeds of oilseed agricultural products as an oleosin fusion facilitate the
extraction of fused proteins from oil bodies and the release of the recombinant proteins from
their fusion partner; one example can be the accumulation and purification of biologically
active human insulin, apolipoprotein A-I (Milano) and human growth hormone in safflower
[63-65].
There are several recombinant proteins derived from plants that were the basic idea of edible
vaccines, directly eaten as fruits (tomatoes and bananas) and vegetables (lettuce and carrots);
accordingly, no processing costs will be demanded by the elimination of processing, [66].
Bananas, as a fruit host in agricultural products, have particularly attracted lots of customers
for the production of edible vaccines, especially for developing countries. This has been widely
developed in such countries because of long distance transports and cooling requirements [42].
Apart from the mentioned advantages, high digestibility and palatability of bananas have won
a wide public acceptance for the vaccination of children [67, 68]. The sufficiency of potatoes,
eaten in raw or low processed forms, for edible vaccines has resulted in their wide production.
Potatoes, like seeds, have the advantage of production stability due to a special molecular
environment allocated in glands [69].
10. Bio-safety and the challenges in the domain of protein production and
biomedicines in molecular farming
The risks of transgenic plants are divided into two categories: one category directly affects
humans and the other endangers environment and other organisms. The attack of immune
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system can disable these medicines and lead to the stimuli for the allergic reactions, some of
which have been elaborated as follows:
• There are some concerns in terms of environmental pollution about the entrance of trans‐
genes into the food chain, which requires a sound management and supervision.
• The other concern refers to the grain transformations using agrobacterium since grains are
important crops in the production of pharmaceutical protein.
• The reactions of immune system can disable the medicines produced in plants and be the
stimuli for allergic reactions [70].
11. Perspectives upon the commercial production of medicines and
pharmaceutical proteins in molecular farming
The development stages and subsequent commercialization of the products is the subject of
consideration in the second phase of clinical trials. A number of small biotechnology compa‐
nies have aimed to commercialize the antibodies produced in plants. It has been estimated that
the increasing annual need for secretory IgA will be 13%, and a rate of $25 billion was predicted
as the annual income of producing IgA in crops. While there have been great advances in the
field of biomedicine production in plants on large scales, fundamental studies are demanded
to pave the way for the commercialization of these products. The present problems include
the difficulty of low yield of protein, the possibility of harmful effects on the function/
performance of proteins due to the differences in glycosylation patterns, and the severe
potential impact of expressing plants of biomedicine plants on the environment (e.g., concerns
upon genetic limitations) [74].
12. Conclusion
The aim of molecular farming is to produce large quantities of active and secure pharmaceut‐
ical proteins with lower prices. With the scientific advances in the field of bio-technology,
nowadays, gene transfer methods in plants have considerably developed. These transgenic
plants in comparison with other microbial and animal expression systems have various
advantages in terms of easy production, cost, safety, etc. for producing pharmaceutical
biomolecules. So far, lots of valuable pharmaceutical proteins and antibodies have been
produced by the help of this method, which remarkably has helped the treatment of patients
especially in developing countries where the production and preservation costs of such
medicines cannot be afforded. However, there are some disputes, such as public acceptance,
transgene escape and biosecurity, clinical and commercialization investigations of products,
etc., which has made it a challenging area, but it is hoped that in near future molecular farming
will witness great achievements with the researchers and scholars' efforts.
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